As shown in Fig. 5a, after treated with Doxorubicin, the MINA53-knockdown groups exhibited a much greater proportion of dead cells than the control groups, indicating that knockdown of MINA53 sensitized glioblastoma cells to Doxorubicin. This evidence concerns the gene RIOX2 and glioblastoma.